CR20130111A - Triazina-oxidiazoles - Google Patents

Triazina-oxidiazoles

Info

Publication number
CR20130111A
CR20130111A CR20130111A CR20130111A CR20130111A CR 20130111 A CR20130111 A CR 20130111A CR 20130111 A CR20130111 A CR 20130111A CR 20130111 A CR20130111 A CR 20130111A CR 20130111 A CR20130111 A CR 20130111A
Authority
CR
Costa Rica
Prior art keywords
oxidiazoles
triazine
Prior art date
Application number
CR20130111A
Other languages
English (en)
Inventor
Oliver Barker
Jonathan Bentley
Mark Gary Bock
Thomas Cain
Praful Chovatia
Jennifer Ruth Dod
Florence Eustache
Laura Gleave
Jonathan Hargrave
Alexander Heifetz
Richard Law
Ali Raoof
David Willows
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US38215810P priority Critical
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20130111A publication Critical patent/CR20130111A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
CR20130111A 2010-09-13 2013-03-13 Triazina-oxidiazoles CR20130111A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US38215810P true 2010-09-13 2010-09-13

Publications (1)

Publication Number Publication Date
CR20130111A true CR20130111A (es) 2013-05-29

Family

ID=44651777

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130111A CR20130111A (es) 2010-09-13 2013-03-13 Triazina-oxidiazoles

Country Status (26)

Country Link
US (2) US8895733B2 (es)
EP (1) EP2616465B1 (es)
JP (1) JP2013537180A (es)
KR (1) KR101843600B1 (es)
CN (1) CN103221408A (es)
AU (1) AU2011303978B2 (es)
BR (1) BR112013005889A2 (es)
CA (1) CA2812081A1 (es)
CL (1) CL2013000685A1 (es)
CO (1) CO6690768A2 (es)
CR (1) CR20130111A (es)
CU (1) CU20130036A7 (es)
DK (1) DK2616465T3 (es)
EA (1) EA026132B1 (es)
ES (1) ES2559449T3 (es)
HR (1) HRP20160094T1 (es)
HU (1) HUE027256T2 (es)
MX (1) MX2013002864A (es)
NZ (1) NZ608116A (es)
PE (1) PE20131377A1 (es)
PL (1) PL2616465T3 (es)
PT (1) PT2616465E (es)
RS (1) RS54544B1 (es)
SG (1) SG188438A1 (es)
SI (1) SI2616465T1 (es)
WO (1) WO2012035023A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101843600B1 (ko) * 2010-09-13 2018-03-29 노파르티스 아게 트리아진-옥사디아졸
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
BR112014010271A2 (pt) 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
BR112014029161A2 (pt) 2012-05-22 2017-06-27 Genentech Inc benzamidas n-substituídas e seu uso no tratamento de dor
RU2015103913A (ru) 2012-07-06 2016-08-27 Дженентек, Инк. N-замещенные бензамиды и способы их применение
CU24387B1 (es) 2012-11-21 2019-03-04 Ptc Therapeutics Inc Inhibidores de bmi-1 de pirimidina inversa sustituida
MX2015011436A (es) 2013-03-14 2016-06-06 Genentech Inc Triazolopiridinas sustituidas y metodos para usarlas.
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
TWI692477B (zh) 2013-08-30 2020-05-01 美商Ptc治療公司 經取代嘧啶bmi-1抑制劑
WO2015076801A1 (en) * 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted triazine bmi-1 inhibitors
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP2018520107A (ja) 2015-05-22 2018-07-26 ジェネンテック, インコーポレイテッド 置換ベンズアミド及びその使用方法
TW201827412A (zh) * 2016-10-13 2018-08-01 英商葛蘭素史克智慧財產發展有限公司 化學化合物
JP2019532077A (ja) 2016-10-17 2019-11-07 ジェネンテック, インコーポレイテッド 治療用化合物及びその使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
EP1187825A1 (en) 1999-06-07 2002-03-20 Shire Biochem Inc. Thiophene integrin inhibitors
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP2256108B1 (en) 2002-07-18 2016-03-23 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
PE20051029A1 (es) * 2003-07-02 2005-12-07 Vertex Pharma Pirimidinas moduladoras de canales ionicos regulados por voltaje
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
US20080227799A1 (en) 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders
NZ581309A (en) * 2007-05-25 2012-02-24 Vertex Pharma Ion channel modulators and methods of use
WO2009002964A1 (en) 2007-06-26 2008-12-31 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
TW200911766A (en) * 2007-07-13 2009-03-16 Astrazeneca Ab New compounds
WO2009091388A2 (en) 2007-12-21 2009-07-23 Progenics Pharmaceuticals, Inc. Triazines and related compounds having antiviral activity, compositions and methods thereof
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8236880B2 (en) 2008-04-23 2012-08-07 Taylor Made Golf Company, Inc. Compositions comprising an amino triazine and ionomer or ionomer precursor
WO2010017368A2 (en) 2008-08-06 2010-02-11 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
WO2010022055A2 (en) * 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
CA2789711C (en) * 2010-02-17 2014-08-05 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
KR101843600B1 (ko) * 2010-09-13 2018-03-29 노파르티스 아게 트리아진-옥사디아졸

Also Published As

Publication number Publication date
KR20130105657A (ko) 2013-09-25
CO6690768A2 (es) 2013-06-17
WO2012035023A1 (en) 2012-03-22
KR101843600B1 (ko) 2018-03-29
NZ608116A (en) 2014-05-30
EA201390381A1 (ru) 2013-08-30
US20150025057A1 (en) 2015-01-22
EA026132B1 (ru) 2017-03-31
EP2616465B1 (en) 2015-11-04
MX2013002864A (es) 2013-08-29
PL2616465T3 (pl) 2016-04-29
HUE027256T2 (en) 2016-08-29
CN103221408A (zh) 2013-07-24
US8895733B2 (en) 2014-11-25
CU20130036A7 (es) 2013-05-31
PT2616465E (pt) 2016-03-09
HRP20160094T1 (en) 2016-02-26
JP2013537180A (ja) 2013-09-30
EP2616465A1 (en) 2013-07-24
AU2011303978B2 (en) 2014-07-03
SI2616465T1 (sl) 2016-02-29
BR112013005889A2 (pt) 2020-08-25
US20140051676A1 (en) 2014-02-20
RS54544B1 (en) 2016-06-30
SG188438A1 (en) 2013-05-31
PE20131377A1 (es) 2013-11-30
CA2812081A1 (en) 2012-03-22
DK2616465T3 (da) 2016-02-01
AU2011303978A1 (en) 2013-03-21
ES2559449T3 (es) 2016-02-12
CL2013000685A1 (es) 2013-10-04

Similar Documents

Publication Publication Date Title
NO2019034I1 (no) lorlatinib
NO2017023I2 (no) Venetoklaks
NO2016004I2 (no) Ledipasvir
NO2019006I1 (no) Tisagenlekleucel
NO2020017I1 (no) Siponimod
NO2019020I1 (no) lanadelumab
SMT201600400B (it) Inalatore
NO2019022I1 (no) Natriumzirkoniumsyklosilikat
NO2019038I1 (no) Risankizumab
CO6811812A2 (es) Anticuerpo anti-b7-h3
CO6990736A2 (es) Pirrolidina-2-carboxamidas sustituídas
CO6910200A2 (es) Derivado de pirazoloquinolina
NO2018039I1 (no) Rukaparibkamsylat
CL2013001223S1 (es) Parlantes
NO20140526A1 (no) Svanehals-ledningssystem
ITVI20100321A1 (it) Bottiglia
CO6910197A2 (es) Compuestos novedosos
NO20131470A1 (no) Bropluggverktøy
NO20120395A1 (no) Stromningsstyringssystem
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
CO6890075A2 (es) Alcoholimetro calibrable
NO2017034I1 (no) Idarucizumab
CO6801726A2 (es) Compuestos
CR20130111A (es) Triazina-oxidiazoles
SMT201500078B (it) Fellosilicato modificato